Efficacy and Safety of Low-Dose Trimethoprim-Sulfamethoxazole (TMP-SMZ) for the Prevention of Pneumocystis jirovecii pneumonia (PJP) in Non-HIV, Non-Transplant Immunosuppressed Patients: A Real-World Cohort Study
In non-HIV, non-transplant, immunosuppressed patients, the efficacy of low-dose TMP-SMZ (200/40 mg/d) in the prevention of PJP was not inferior to that of conventional-dose TMP-SMZ, and the safety profiles of the two doses were equivalent.
Authors
- Juanfen Mo (ORCID: https://orcid.org/0000-0002-5858-1659)
- Dakui Cao
- Hua Zhou (ORCID: https://orcid.org/0000-0001-6397-3203)
- Z. Q. Zhu (ORCID: https://orcid.org/0000-0001-7175-3307)
- Jianping Jiang (ORCID: https://orcid.org/0000-0003-1120-6883)
- Haiqin Wang (ORCID: https://orcid.org/0000-0002-4969-220X)
- Mengqing Cao
Institutions
- First Hospital of Jiaxing (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Infection and Drug Resistance
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/idr.s549404
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00